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Introduction {#sec1}
============

Drug transporting membrane proteins are major determinants of the disposition of many registered drugs and are, therefore, of great relevance for drug safety and efficacy. This has stimulated a considerable interest in developing a better understanding of interactions with transporters already at the drug discovery stage. The organic anion transporting polypeptide 1B1 (OATP1B1/*SLCO1B1*) transporter is one of the most highly expressed uptake transporters in human liver.^[@ref1]^ OATP1B1 has, along with OATP1B3 (*SLCO1B3*), been shortlisted as a transporter of considerable importance for drug disposition.^[@ref2]^ The significance of OATP1B1 has further been emphasized by numerous reports regarding OATP1B1 mediated clinical drug--drug interactions (DDIs)^[@ref3]^ as well as the identification of this transporter as an important pharmacogenomic biomarker for simvastatin-induced adverse drug effects.^[@ref4]^ OATP1B1, OATP1B3, and the less studied OATP2B1 (*SLCO2B1*) transporter are all localized in the basolateral membrane of human hepatocytes. They mediate the uptake of xenobiotics and endogenous compounds from the portal bloodstream into the hepatocytes. For substrate drugs, transport proteins, such as the OATPs, determine intracellular concentrations and, hence, exposure to drug metabolizing enzymes. Examples of drugs and drug classes that are substrates of the OATPs are 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) inhibitors (statins), bosentan, and angiotensin II-receptor antagonists.^[@ref2],[@ref3]^ Although there is a large substrate overlap between the three hepatic OATPs, some compounds have been described as specific substrates of one or another of the OATPs, e.g., pitavastatin and prostaglandin E2 as OATP1B1 specific substrates,^[@ref5]^ and paclitaxel and the gastrointestinal peptide hormone cholecystokinin octapeptide (CCK-8) as OATP1B3 specific substrates.^[@ref3],[@ref6]^

Although, we have a relatively good understanding of OATP substrates as well as OATP1B1 interacting drugs to date (cf. refs ([@ref3],[@ref7])), limited data is available regarding OATP1B3 and OATP2B1 interacting drugs. So far, no global comparisons of the known OATP interacting drugs, nor of the molecular features of importance for inhibition of the three OATPs in the human liver, have been made. Knowledge about specific and general inhibitors of these transporters would be of great value in revealing transport in complex systems like hepatocytes.

A crucial factor for increasing the knowledge and predictability of drug disposition is the establishment of in vitro to in vivo correlations. A prerequisite for assessing and comparing the importance of transport proteins, as well as the impact of drug interactions in vivo, is knowledge of the maximal transport activity (MTA) of each transport protein in the tissue of interest; in this case, of OATPs in the human liver. Because deep tissue measurements cannot be routinely performed in humans for ethical reasons, ways to extrapolate in vitro activity to in vivo conditions need to be developed. The transport activity is dependent on the amount of functional transporter. Therefore, information about tissue expression of transport proteins would be beneficial in the estimation of MTA, and for the subsequent prediction of the impact of various DDIs.

The aims of this study were: (i) to identify specific and general inhibitors of the three hepatic OATPs (OATP1B1, OATP1B3, and OATP2B1), (ii) to study the inhibition patterns of OATP1B1, OATP1B3, and OATP2B1 and the molecular features that determine inhibition, and (iii) to determine the protein expression of OATP1B1, OATP1B3, and OATP2B1 in human liver and in in vitro cell models in order to calculate the maximal hepatic transport activity and, thereby, predict the importance of each OATP for uptake clearance (CL) and DDIs in vivo.

To meet these aims, we developed in vitro screening models for rapid identification of OATP inhibition. We have applied these models to investigate the inhibition potential of 225 drugs and drug-like compounds on OATP1B1, OATP1B3, and OATP2B1 mediated transport. Our experimental data were used to develop multivariate computational models predicting specific or general OATP interactions based on physicochemical properties of the studied compounds. For a selected subset of 13 compounds, concentration dependent inhibition of each OATP was studied and compounds that could be used as selective or general OATP inhibitors were identified. Further, the protein expression of OATP1B1, OATP1B3, and OATP2B1 was determined in human liver and in the in vitro cell models. The results were used to calculate the intrinsic hepatic uptake CL of atorvastatin for each OATP and to determine the contribution of each transport protein to drug interactions, using a subset of identified inhibitors.

Results {#sec2}
=======

Characteristics of the Data Set {#sec2.1}
-------------------------------

The data set of 225 compounds used in this study was selected mainly from the chemical space of oral drugs. An in-house data set of 142 compounds, enriched in OATP inhibitors,^[@ref7]^ was used as a starting point. This data set was expanded with compounds known to interact with other hepatic transporters and with the major cytochrome P450 (CYP) enzymes involved in drug elimination, giving a final data set of 225 compounds. A principal component analysis (PCA) of the data set resulted in two significant components that described 78% of the chemical variation of the data set. The first principal component was mainly governed by polarity and hydrogen bonding, while the second principal component was mainly described by lipophilicity. The data set was well distributed in the oral drug space (see Figure [1](#fig1){ref-type="fig"}a). Outliers included large compounds such as rifampicin and cyclosporine A.

![Principal components analysis (PCA) of an oral drug reference data set^[@ref8]^ (gray squares; *n* = 529) and the data set of 225 compounds investigated for OATP inhibition (black squares; *n* = 225) (a). The circle indicates the 95% confidence interval of the PCA for the oral drug reference data set. The first principal component (*x*-axis) is governed by polarity and hydrogen bonding, which increases to the right, whereas the second principal component (*y*-axis) is governed by lipophilicity, which increases upward. Distribution of molecular charge at pH 7.4 of the 225 compounds investigated for OATP inhibition (b).](jm-2012-00212s_0002){#fig1}

The physicochemical descriptors of all the compounds are summarized in Table [1](#tbl1){ref-type="table"} and in [Supporting Information Table 1](#notes-1). The molecular weight distribution ranged from 94.1 to 1214.6 g/mol, with a mean ± standard deviation of 401.6 ± 191.3 g/mol, which is higher than the mean of orally administered drugs (347 ± 162 g/mol^[@ref8]^). This is a result of the inclusion of compounds known to interact with the OATPs, e.g., protease inhibitors, which tend to be larger than average oral drugs.^[@ref7]^ The lipophilicity, as indicated by NNLogP, varied between −2.8 and 7.2, with a mean of 2.7 ± 1.9 and the average polar surface area (PSA) was 96.1 ± 70.2 Å^2^, which is in line with the range of conventional registered oral drugs. The data set included 22% positively charged compounds, 29% negatively charged compounds, 43% neutral compounds, and 6% zwitterionic compounds at pH 7.4 (see Figure [1](#fig1){ref-type="fig"}b). Because the data set was enriched in compounds interacting with the OATP transporters (i.e., mainly neutral or negatively charged compounds),^[@ref7]^ a higher fraction of neutral and negatively charged compounds was found in this data set compared to the corresponding fraction in the oral drug space.

###### Inhibitory Effect on OATP1B1, OATP1B3, and OATP2B1 Mediated Transport and Molecular Descriptors of the 225 Investigated Compounds (The Complete Table Including Additional Molecular Descriptors Can Also Be Found in [Supporting Information Table 1](#notes-1).)
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Inhibition of OATP1B1 mediated E17βG uptake at 20 μM. Substrate concentration used was 0.52 μM.

Inhibition of OATP1B3 mediated E17βG uptake at 20 μM. Substrate concentration used was 1.04 μM.

Inhibition of OATP2B1 mediated E3S uptake at 20 μM. Substrate concentration used was 1.02 μM.

AZ oeSelma descriptors generated from SMILES ([Supporting Information Table 4](#notes-1)). Compounds were treated in their neutral states.

Predicted charge at pH 7.4 (based on p*K*~a~ values obtained using ADMET Predictor (SimulationsPlus, Lancaster, CA, USA)). + and -- denotes positively and negatively charged compounds, respectively. n denotes neutral compounds and ± denotes zwitterionic compounds.

Predicted solubility (using ADMET Predictor (SimulationsPlus, Lancaster, CA, USA)) in water at pH 7.4 is lower than 20 μM. However, it should be noted that all compounds are first dissolved in DMSO and further diluted with HBSS buffer giving a final DMSO concentration ≤1% in all experiments.

Values from Karlgren et al.^[@ref7]^

Compounds or compound groups suggested as OATP1B1 substrates by Giacomini et al.^[@ref2]^

Compounds or compound groups suggested as OATP1B3 substrates by Giacomini et al.^[@ref2]^

Compounds or compound groups suggested as OATP2B1 substrates by Giacomini et al.^[@ref2]^

Compounds suggested as OATP1B1 inhibitors by Giacomini et al.^[@ref2]^

Compounds suggested as OATP1B3 inhibitors by Giacomini et al.^[@ref2]^

Compounds suggested as OATP2B1 inhibitors by Giacomini et al.^[@ref2]^

Transport Kinetics {#sec2.2}
------------------

Human embryonic kidney 293 (HEK293) cells were stably transfected with OATP1B1, OATP1B3, or OATP2B1. On the basis of all experiments (*n* = 12 (OATP1B1), *n* = 66 (OATP1B3), *n* = 51 (OATP2B1)), the mean uptake of the model substrates, estradiol-17β-glucuronide (E17βG) or estrone-3-sulfate (E3S) in the OATP expressing HEK293 cells, increased 13 times (OATP1B1), 6.5 times (OATP1B3), and 44 times (OATP2B1) compared to the passive uptake in mock-transfected cells (for a representative experiment see Figure [2](#fig2){ref-type="fig"}a--c). The uptake curves of model substrates and atorvastatin (used in the in vitro--in vivo extrapolations), as well as resulting kinetic parameters, are in line with available published data^[@ref7],[@ref9]^ and are presented in Figure [2](#fig2){ref-type="fig"}d--f, Table [2](#tbl2){ref-type="table"}, and [Supporting Information Figure 1](#notes-1). For all curves, both a saturable (OATP dependent) and a linear (passive diffusion) component were observed.

![Uptake of estradiol-17β-glucuronide (E17βG) in OATP1B1 (a) and OATP1B3 (b) and of estrone-3-sulfate (E3S) in OATP2B1 expressing HEK293 cells (c) as compared to the passive uptake in mock transfected cells in one representative experiment. Substrate concentrations used were 0.52, 1.04, and 1.02 μM for OATP1B1, OATP1B3, and OATP2B1, respectively. Bars represent mean ± standard deviation (OATP1B1 and OATP2B1) or mean ± range (OATP1B3). Michaelis--Menten kinetics of model substrate uptake in HEK293 cells stably expressing the OATP1B1 (d), OATP1B3 (e), or OATP2B1 (f) transporter. The intracellular accumulation of the radiolabeled substrates was measured on a scintillation counter. Each data point in the OATP1B1 and OATP2B1 curves represents the mean uptake ± standard error, whereas in the OATP1B3 curve, each replicate is shown.](jm-2012-00212s_0003){#fig2}

###### Kinetic Parameters of OATP1B1, OATP1B3, and OATP2B1 Mediated Transport

                                            substrate                   *K*~m~ (μM)     *V*~max~ (pmol/mg protein/min)   *V*~max~/*K*~m~ (μL/mg protein/min)
  ----------------------------------------- --------------------------- --------------- -------------------------------- -------------------------------------
  OATP1B1                                   estradiol-17β-glucoronide   12.20 ± 5.94    15.44 ± 3.44                     1.27
  OATP1B3                                   estradiol-17β-glucoronide   11.69 ± 3.80    10.12 ± 1.78                     0.86
  OATP2B1                                   estrone-3-sulfate           38.24 ± 10.19   455.2 ± 55.36                    11.90
  OATP1B1[a](#t2fn1){ref-type="table-fn"}   atorvastatin                0.77 ± 0.24     6.61 ± 1.24                      8.58
  OATP1B3                                   atorvastatin                0.73 ± 1.45     2.29 ± 1.45                      3.14
  OATP2B1                                   atorvastatin                2.84 ± 1.63     24.27 ± 8.12                     8.55

Values from Karlgren et al.^[@ref7]^

Interaction with the OATP Transporters {#sec2.3}
--------------------------------------

The screening of the 225 compounds for interaction with each individual OATP was performed at a concentration of 20 μM, as described in the [Experimental Details](#sec4). A compound was classified as an inhibitor if it significantly decreased the uptake of model substrate by at least 50%. In the OATP1B1 interaction study, 78 (35%) of the 225 compounds analyzed were classified as OATP1B1 inhibitors (see Figure [3](#fig3){ref-type="fig"} and Table [1](#tbl1){ref-type="table"}). Of these, four compounds (coumestrol, diazepam, nifedipine, and novobiocin) have not, to our knowledge, previously been reported to interact with OATP1B1. In the OATP1B3 and OATP2B1 interaction studies, 46 (20%) and 45 (20%) inhibitors were identified, respectively (Figure [3](#fig3){ref-type="fig"} and Table [1](#tbl1){ref-type="table"}). Of the 46 identified inhibitors of OATP1B3, 16 have not, to our knowledge, previously been reported to interact with OATP1B3. Of the 45 compounds identified as OATP2B1 inhibitors, 29 compounds were identified as novel inhibitors and have not, to our knowledge, been reported to interact with OATP2B1 in any other studies. All novel OATP inhibitors identified in this study are summarized in Table [3](#tbl3){ref-type="table"}.

![Inhibition potency of all 225 compounds on OATP1B1 (a), OATP1B3 (b), and OATP2B1 mediated transport (c) at a concentration of 20 μM. Values are presented as mean percent inhibition ± standard deviation. The 50% cutoff value is indicated by the dashed lines. Compounds identified as inhibitors (inhibition ≥50%) are shown in dark gray, while compounds identified as noninhibitors or stimulators are shown in medium gray. In total, 78, 46, and 45 inhibitors of OATP1B1, OATP1B3, and OATP2B1 were identified, respectively. For OATP1B1, inhibition values for 142 of the 225 compounds were taken from the study by Karlgren et al.^[@ref7]^.](jm-2012-00212s_0004){#fig3}

###### Novel OATP Inhibitors Identified

  compound                                  new inhibitor of            previously known OATP interaction                                                          ref
  ----------------------------------------- --------------------------- ------------------------------------------------------------------------------------------ --------------------------------------
  5-carboxyfluorescein diacetate (5-CFDA)   OATP1B3                     OATP1B1 inhibitor                                                                          ([@ref7])
  astemizole                                OATP2B1                                                                                                                 
  baicalin                                  OATP2B1                                                                                                                 
  benzbromarone                             OATP2B1                     OATP1B1 inhibitor                                                                          ([@ref7],[@ref49])
  cholecystokinin octapeptide (CCK-8)       OATP2B1                     OATP1B1 substrate and inhibitor, OATP1B3 substrate, Oatp1b2 substrate, Oatp1b4 substrate   ([@cit5a],[@cit6a],[@ref7],[@ref50])
  coumestrol                                OATP1B1                                                                                                                 
  diazepam                                  OATP1B1, OATP2B1                                                                                                        
  diethylstilbestrol                        OATP2B1                     OATP1B1 inhibitor                                                                          ([@ref7])
  dipyridamole                              OATP1B3, OATP2B1            OATP1B1 inhibitor                                                                          ([@ref7])
  erlotinib                                 OATP2B1                                                                                                                 
  fluo-3                                    OATP2B1                     OATP1B3 substrate                                                                          ([@ref51])
  flutamide                                 OATP2B1                                                                                                                 
  genistein                                 OATP2B1                     OATP1B1 inhibitor                                                                          ([@ref52])
  GF120918 (elacridar)                      OATP2B1                     OATP1B1 inhibitor                                                                          ([@ref7])
  glycochenodeoxycholate                    OATP1B3,OATP2B1             OATP1B1 inhibitor, Oatp1a5 substrate                                                       ([@ref7],[@ref53])
  glycodeoxycholate                         OATP1B3,OATP2B1             OATP1B1 inhibitor, Oatp1a5 substrate                                                       ([@ref7],[@ref53])
  Hoechst 33342                             OATP1B3                                                                                                                 
  indocyanine green                         OATP2B1                     OATP1B3 substrate, OATP1A2, OATP1B1, OATP1B3, Oatp2a1, Oatp1a1 and Oatp1c1 inhibitor       ([@ref54])
  itraconazole                              OATP2B1                                                                                                                 
  ivermectin                                OATP1B3                     OATP1B1 inhibitor                                                                          ([@ref7])
  KO143                                     OATP2B1                                                                                                                 
  levothyroxin                              OATP2B1                     OATP1A2, OATP1B1, OATP1C1, Oatp1a4, Oatp1a5, Oatp1c1 and Oatp4a1 substrate                 ([@ref55])
  morin                                     OATP1B3,OATP2B1             OATP1B1 substrate and inhibitor                                                            ([@ref52])
  nefazodone                                OATP1B3, OATP2B1                                                                                                        
  nelfinavir                                OATP1B3                     OATP1A2, OATP1B1 and OATP2B1 inhibitor                                                     ([@ref56])
  nifedipine                                OATP1B1                                                                                                                 
  novobiocin                                OATP1B1, OATP1B3, OATP2B1                                                                                               
  nystatin                                  OATP1B3                     OATP1B1 inhibitor                                                                          ([@ref7])
  piroxicam                                 OATP2B1                                                                                                                 
  PSC833 (valspodar)                        OATP1B3                     OATP1B1, Oatp1 and Oatp2 inhibitor                                                         ([@cit56a],[@ref57])
  reserpine                                 OATP2B1                     OATP1B1 inhibitor                                                                          ([@ref7])
  silymarin                                 OATP1B3, OATP2B1            OATP1B1 inhibitor                                                                          ([@ref52],[@ref58])
  sulfasalazine                             OATP1B3, OATP2B1            OATP1B1 inhibitor                                                                          ([@ref7])
  taurodeoxycholate                         OATP2B1                     OATP1B3, Oatp1a1 and Oatp1a5 substrate                                                     ([@cit53b],[@cit53c])
  taurolithocholate                         OATP1B3, OATP2B1            OATP1B1 substrate, OATP1B1 and skate Oatp inhibitor                                        ([@ref7],[@ref59])
  tetracycline                              OATP2B1                                                                                                                 
  tipranavir                                OATP1B3                     OATP1B1 and OATP2B1 inhibitor                                                              ([@ref7],[@ref60])
  valproic acid                             OATP2B1                                                                                                                 

A few compounds stimulated, rather than inhibited, the OATP mediated transport (see Figure [3](#fig3){ref-type="fig"} and Table [1](#tbl1){ref-type="table"}). Using an equivalent definition of stimulators as of inhibitors, i.e., a stimulator increases the transport of substrate at least 2-fold, clotrimazole was identified as a stimulator of OATP1B3 mediated uptake of E17βG, while fendiline, progesterone, and testosterone were found to stimulate the transport of E3S by OATP2B1. Of these identified stimulators, fendiline is a novel OATP2B1 stimulator, not previously reported to interact with any OATP. Stimulation of OATP1B3 and OATP2B1 mediated uptake by clotrimazole and progesterone has been reported previously.^[@ref10],[@ref11]^ Testosterone, here identified as an OATP2B1 stimulator, has previously been reported to be an OATP2B1 inhibitor.^[@ref11]^ This result is analogous with, e.g., results for the ABC transporter multidrug resistance associated protein 2 (MRP2), where interacting compounds have been shown to serve as both stimulators and inhibitors depending on concentration used and other experimental factors.^[@ref12]^

Identification of OATP Inhibitor Overlap Using the Single-Point Inhibition Results {#sec2.4}
----------------------------------------------------------------------------------

In total, 91 of the 225 investigated compounds were identified to interact with one or more of the three OATP transporters. The number of OATP1B1 inhibitors was almost twice as high as those of OATP1B3 or OATP2B1 (see previous section). Twenty-seven compounds that only inhibit OATP1B1 were identified from the screens. This can be compared with three and nine compounds classified as specific inhibitors of OATP1B3 and OATP2B1, respectively (see Figure [4](#fig4){ref-type="fig"} and Table [1](#tbl1){ref-type="table"}). The three hepatic OATP transporters displayed a large inhibitor overlap, with 26 compounds identified as common inhibitors. OATP1B1 and OATP1B3 had the greatest similarity in inhibition pattern, with 42 inhibitors in common. Of these, 16 did not significantly decrease OATP2B1 mediated transport at 20 μM used in the screening assay. In contrast, only one compound (nefazodone) was identified as an inhibitor of both OATP1B3 and OATP2B1 while not interacting with OATP1B1.

![Inhibitor overlap for the three investigated OATP transporters OATP1B1 (yellow), OATP1B3 (red), and OATP2B1 (blue). In total, 91 (40%) of the 225 compounds screened inhibited at least one of the OATP transporters studied. The number of specific inhibitors of OATP1B1, OATP1B3, and OATP2B1 were 27, 3, and 9, respectively. Larger inhibitor overlaps were seen between OATP1B1 and OATP1B3, and between OATP1B1 and OATP2B1, than between OATP1B3 and OATP2B1. As many as 26 compounds were identified as inhibitors of all three transporters at the studied concentration (20 μM).](jm-2012-00212s_0005){#fig4}

Of the 225 compounds included in this study, 67 substances are suggested as CYP substrates, inhibitors, or inducers by the Food and Drug Administration (FDA) and/or the European Medicines Agency (EMA).^[@ref13]^ Twenty-one of these 67 compounds also inhibited one or several of the OATP transporters, indicating an interaction overlap between OATP transporters and CYP enzymes. The largest overlap was seen for CYP2C8 where 73% of the interacting compounds also inhibited one or several of the OATP transporters, as illustrated in [Supporting Information Figure 2](#notes-1). These results are now further investigated in our group.

Molecular Characteristics of the OATP Inhibitors {#sec2.5}
------------------------------------------------

The identified inhibitors were compared with the noninhibitors with regard to physicochemical properties. Compounds that stimulated substrate uptake were excluded from the analysis of each data set. In general, the identified OATP inhibitors had a significantly higher lipophilicity, a larger molecular weight, and a larger PSA compared to noninhibitors (see Table [4](#tbl4){ref-type="table"} and Figure [5](#fig5){ref-type="fig"}a--b). As expected from the annotation of OATPs as anion transporters, a significantly larger fraction of negatively charged compounds was found among the inhibitors. The importance of lipophilicity, as well as polarity and hydrogen bonding, for OATP inhibition was also evident from the PCA of the data set, where the inhibitors were clustered in the upper right corner of the PCA graph (with the first principal component mainly described by polarity and hydrogen bonding, and the second principal component mainly governed by lipophilicity) as shown in Figure [5](#fig5){ref-type="fig"}c.

###### Difference in Physicochemical Properties between Inhibitors (≥ 50% Inhibition) and Noninhibitors (0--50% Inhibition) of OATP1B1, OATP1B3, and OATP2B1, Respectively (Median Descriptor Values Are Presented)

                                 OATP1B1         
  ------------------------------ --------- ----- ----------
  NNLogP                         3.6       2.3   \<0.0001
  polar surface area (Å^2^)      121       66    \<0.0001
  nonpolar surface area (Å^2^)   454       307   \<0.0001
  total surface area (Å^2^)      564       363   \<0.0001
  molecular weight (g/mol)       481       325   \<0.0001
  negative charge (%)            53        18    \<0.0001
  hydrogen bond acceptors        5         3     \<0.0001
  hydrogen bond donors           2         2     ns

                                 OATP1B3         
  ------------------------------ --------- ----- ----------
  NNLogP                         3.8       2.7   0.0001
  polar surface area (Å^2^)      142       70    \<0.0001
  nonpolar surface area (Å^2^)   492       307   \<0.0001
  total surface area (Å^2^)      609       369   \<0.0001
  molecular weight (g/mol)       514       336   \<0.0001
  negative charge (%)            59        23    \<0.0001
  hydrogen bond acceptors        7         3     \<0.0001
  hydrogen bond donors           3         2     0.0007

                                 OATP2B1         
  ------------------------------ --------- ----- ----------
  NNLogP                         4.0       2.3   \<0.0001
  polar surface area (Å^2^)      115       74    0.0005
  nonpolar surface area (Å^2^)   456       316   0.0004
  total surface area (Å^2^)      551       369   \<0.0001
  molecular weight (g/mol)       482       333   \<0.0001
  negative charge (%)            60        24    \<0.0001
  hydrogen bond acceptors        5         4     0.0012
  hydrogen bond donors           2         2     n.s.

![Differences in molecular properties between inhibitors and noninhibitors of the OATPs. Distribution of polar surface area (PSA) (a) and lipophilicity (NNLogP) (b) for the OATP inhibitors (black bars) and the noninhibitors (gray bars). The OATP inhibitors have a significantly higher PSA and lipophilicity than the noninhibitors, as assessed using the nonparametric Mann--Whitney U test. Principal component analysis (PCA) of the 225 compounds investigated for OATP inhibition (c). OATP inhibitors are shown as black squares and noninhibitors as gray squares. The first principal component (*x*-axis) is governed by polarity and hydrogen bonding, which increases to the right, whereas the second principal component (*y*-axis) is governed by lipophilicity, which increases upward.](jm-2012-00212s_0006){#fig5}

Although the physicochemical properties identified as important for inhibition of each of the three OATPs were similar, some differences were observed. While inhibitors of OATP1B3 had more hydrogen bond donors than noninhibitors, no significant difference in the number of hydrogen bond donors was observed between the inhibitor and noninhibitor group of OATP1B1 and OATP2B1. In addition, OATP2B1 inhibitors seemed to be less dependent on polarity than OATP1B1 and OATP1B3 inhibitors based on the importance of PSA (see Table [4](#tbl4){ref-type="table"}).

In Silico Prediction of OATP Inhibition {#sec2.6}
---------------------------------------

A computational multivariate partial least-squares projection to latent structures (PLS) model, discriminating inhibitors of any OATP transporter from noninhibitors, was developed. This resulted in a model based on only two molecular descriptors, NNLogP and PSA. The model was able to predict OATP inhibitors with accuracies of 85% and 79% for the training and test set, respectively. The line of optimal separation between the two classes (as depicted in Figure [6](#fig6){ref-type="fig"}) was described by the following equation:

![Discrimination between inhibitors and noninhibitors of the OATPs using two variables only: NNLogP and PSA. The corresponding model separated the two classes (here visualized with a black line) with an accuracy of 85% for the training set and 79% for the test set.](jm-2012-00212s_0007){#fig6}

In addition, multivariate PLS models, discriminating inhibitors of each individual OATP from noninhibitors, were also developed. The final models predicted OATP1B1, OATP1B3, and OATP2B1 inhibitors with accuracies of 73%, 81%, and 77%, respectively, for the training sets and 79%, 92%, and 75%, respectively, for the test sets (see Figure [7](#fig7){ref-type="fig"}a--b). The classification cutoff values^[@ref14]^ for the three models, i.e., OATP1B1, OATP1B3, and OATP2B1, were 0.40, 0.36, and 0.32, respectively, as determined by the training sets. The resulting regression coefficients, reflecting lipophilicity, dipole moment, polarity, nonpolarity, hydrogen bonding, orbital π-energy, size, and rigidity, for the three discriminating models are depicted in Figure [7](#fig7){ref-type="fig"}c--e.

![Accuracy of the prediction of OATP1B1, OATP1B3, and OATP2B1 inhibitors and noninhibitors in the training set (a) and in the test set (b) for the developed individual PLS models. The bars represent the percentage of correctly classified inhibitors (black) and noninhibitors (gray). Comparison of the PLS regression coefficients for the molecular descriptors included in the final discriminating models and their correlation to inhibitors, or noninhibitors, for the OATP1B1 (c), OATP1B3 (d), and OATP2B1 model (e). Descriptors with large absolute coefficients have a large influence on the discriminant model. The included descriptors are Hückel molecular orbital π-energy (HMO pi-energy), total hydrogen bond acceptor strength (HYBOT_sum_acceptor), total hydrogen bond (hydrogen bond acceptors and donors) strength (HYBOT_sum_total), number of hydrogen bond acceptors (HB-acceptors), polar surface area (PSA), total surface area (TSA), nonpolar surface area (NPSA), dipole moment based on Gasteiger atomic charges (Dipole moment Gast.), number of rigid fragments in the molecule (Num. rig. frag.), two-dimensional dipole moment (Dip. mom. 2D (G+H)) and lipophilicity (NNLogP).](jm-2012-00212s_0008){#fig7}

Specific and General OATP Inhibitors Based on IC~50~ Determinations {#sec2.7}
-------------------------------------------------------------------

From the overlapping and specific OATP inhibitors in Table [1](#tbl1){ref-type="table"}, a subset of 13 compounds was chosen for determinations of half-maximal inhibitory concentrations (IC~50~) and subsequent inhibition constants (*K*~i~). The subset included three compounds previously suggested as general OATP inhibitors (cyclosporine A, rifampicin, and ritonavir)^[@ref2]^ and three compounds commonly used as inhibitors of different efflux (ABC) transporters (Hoechst 33342, KO143, and MK571).^[@ref8]^ In addition, to include potential "OATP specific" inhibitors in a broader sense, OATP inhibitors not previously identified as inhibitors of multidrug resistance protein 1 (MDR1), breast cancer resistance protein (BCRP), MRP2, and/or organic cation transporter 1 (OCT1) in published studies^[@ref8],[@ref15]^ were included based on the single-point inhibition studies. Of these, five compounds were classified as specific inhibitors of one of the OATP transporters (indometacin, vincristine, doxorubicin, erlotinib, and pravastatin) and two compounds were classified as general OATP inhibitors (atazanavir and sulfasalazine). Chemical structures of the 13 compounds are provided in Figure [8](#fig8){ref-type="fig"}.

![Molecular structures of the 13 inhibitors selected for experimental determination of IC~50~ values. Compounds identified as selective inhibitors of a single OATP transporter are shown in the top section. Partially overlapping inhibitors (i.e., inhibiting two of the three OATP transporters) are shown in the middle section, and below, in the bottom section, general inhibitors of the OATPs are displayed. The inhibitors are grouped according to transporter preference based on the IC~50~ experiments (see [Results](#sec2)). For KO143, complete inhibition curves could not be generated and, hence, its placement was based on the highest concentration used.](jm-2012-00212s_0009){#fig8}

IC~50~ curves, IC~50~, and *K*~i~ values of the 13 compounds are summarized in Figure [9](#fig9){ref-type="fig"}. Because low substrate concentrations were used in all experiments (i.e., well below *K*~m~), the calculated *K*~i~ values were close to the experimentally determined IC~50~ values for all compounds. The obtained IC~50~ curves verified the trend seen in the single-point inhibition assays. Using the same definition of an inhibitor as in the single-point inhibition studies, i.e., an IC~50~ ≤ 20 μM, 34 of the 35 IC~50~ values resulted in the same classification as in the single-point inhibition assays. The only exception was Hoechst 33342, which did not classify as an OATP1B1 inhibitor in the single-point inhibition assay (48% inhibition at 20 μM) but had an IC~50~ value of 19 μM.

![Concentration dependent inhibitory effect of atazanavir (a), cyclosporine A (b), doxorubicin (c), erlotinib (d), Hoechst 33342 (e), indometacin (f), KO143(g), MK571 (h), pravastatin (i), rifampicin (j), ritonavir (k), sulfasalazine (l), and vincristine (m) on OATP1B1 (black triangles, dashed black line), OATP1B3 (red circles, dotted red line), and OATP2B1 (open squares, solid blue line) mediated transport. IC~50~ and *K*~i~ values were determined using Prism v.4.02 (GraphPad Software, La Jolla, CA, USA) and eqs [4](#eq4){ref-type="disp-formula"}--[5](#eq5){ref-type="disp-formula"}. Tabulated IC~50~ and *K*~i~ values of the 13 selected compounds (n). Erlotinib and pravastatin show selective inhibition of OATP2B1 and OATP1B1, respectively. Cyclosporine A and rifampicin can be considered as OATP1B1/OATP1B3 inhibitors with IC~50~ values of 1.2--1.5 μM for both OATP1B1 and OATP1B3 but more than one log unit higher IC~50~ values (about 30--40 times higher) for OATP2B1. A similar pattern is seen for vincristine, although this compound is a weaker OATP1B1/OATP1B3 inhibitor. Indometacin and sulfasalazine were borderline general inhibitors but with a preference for OATP1B1. Atazanavir, doxorubicin, Hoechst 33342, MK571, and ritonavir had comparable affinity for the three OATP transporters with IC~50~ values being within one log unit.](jm-2012-00212s_0010){#fig9}

As in our previous study on ABC transporters, we classified an inhibitor as selective if it had a greater than 10-fold lower IC~50~ value as compared to those of the other two OATP transporters.^[@ref8]^ Using this definition, pravastatin (IC~50~ of 3.6 μM) and erlotinib (IC~50~ of 0.55 μM) were classified as selective inhibitors of OATP1B1 and OATP2B1, respectively. Cyclosporine A and rifampicin, both previously proposed for use as general OATP inhibitors,^[@ref2]^ were identified as OATP1B1/OATP1B3 inhibitors in the single-point inhibition assays. The IC~50~ determination confirmed these findings. Vincristine, identified as a specific inhibitor of OATP1B3 in the single-point inhibition assays, only had a 4-fold lower IC~50~ value for OATP1B3 than for OATP1B1 (11 μM compared to 44 μM) and was thus, like cyclosporine A and rifampicin, classified as an OATP1B1/OATP1B3 inhibitor. Atazanavir, MK571, and ritonavir were here identified as general OATP inhibitors (IC~50~ values within one log unit) with IC~50~ values ranging between 0.4 and 5.2 μM, 2.9 and 6.4 μM, and 1.3 and 6.1 μM, respectively. Hoechst 33342 was also classified as a general OATP inhibitor, although with a preference for OATP1B1/OATP1B3 and higher IC~50~ values as compared to the general inhibitors listed above. Indometacin and sulfasalazine were classified as borderline general inhibitors but with a preference for OATP1B1. Doxorubicin inhibited all three transporters but at even higher concentrations (IC~50~ values of 41--240 μM). Because of low solubility, complete inhibition curves could not be generated for the BCRP specific inhibitor KO143. However, because this compound completely inhibits BCRP at a lower concentration (1 μM)^[@ref8]^ than concentrations affecting the OATPs, we conclude that it retained its BCRP specificity.

Prediction of IC~50~ Values from Inhibition Studies at a Single Concentration {#sec2.8}
-----------------------------------------------------------------------------

In parallel to experimental IC~50~ determinations, IC~50~ values for the selected subset of 13 compounds were predicted based on the percent inhibition obtained at 20 μM in the single-point inhibition experiments using eq [6](#eq6){ref-type="disp-formula"} (see [Experimental Details](#sec4)). These predicted IC~50~ values were compared to the experimentally determined values. The predicted IC~50~ values agreed reasonably well with the experimental values (see [Supporting Information Figure 3](#notes-1)). Only two predicted values were more than 10-fold different from the experimental values, and, in total, 68% of the predicted values were less than 3-fold different from the obtained values. This observation further supports the applicability of simple screening protocols such as those used in this study.

Prediction of Hepatic Intrinsic Uptake Clearance from Maximal Transport Activity {#sec2.9}
--------------------------------------------------------------------------------

To accurately assess the importance of the three hepatic OATPs in vivo, determination of the MTA of each transport protein in the human liver is required. Because transport capacity is related to the amount of functional transport protein, we determined the membrane protein expression in human liver samples and in our in vitro cell models. We then related the protein expression to observed maximal transport rates (*V*~max~ values) in the in vitro systems and used these data together with expression data from the human liver to calculate the MTA in vivo (see eq [7](#eq7){ref-type="disp-formula"}).

### Relative and Targeted Protein Quantification of OATP Expression in Human Liver {#sec2.9.1}

To obtain an appreciation of the variability in the liver transporter expression and to select a representative sample for targeted protein quantification, the relative protein expressions of OATP1B1, OATP1B3, and OATP2B1 were first determined in membrane fractions of human liver from 12 individuals using a filter-aided sample preparation (FASP) based proteomics approach.^[@ref16]^ On the basis of these results, a sample, representative of the average OATP protein expression (filled circle in Figure [10](#fig10){ref-type="fig"}a), was selected and used for the subsequent targeted protein quantification. The expression of OATP1B1, OATP1B3, and OATP2B1 was compared with the corresponding data obtained in the in vitro HEK293 cells overexpressing OATP1B1, OATP1B3, and OATP2B1, respectively (Figure [10](#fig10){ref-type="fig"}b--c). As determined by the peptide-based targeted protein quantifications, the levels of OATPs (liver vs overexpressing HEK293 cells) were found to be 7.2 ± 0.3 vs 12.1 ± 0.9 (OATP1B1), 6.3 ± 0.4 vs 4.7 ± 0.4 (OATP1B3), and 4.0 ± 0.4 vs 57.3 ± 2.5 fmol/μg membrane protein (OATP2B1), respectively.

![Prediction of in vivo intrinsic uptake clearance (CL~int,uptake~) based on protein expression data. Relative membrane protein expression of OATP1B1, OATP1B3, and OATP2B1 in 12 human liver samples (a). One sample (filled black circle), with relative expression levels close to the average expression of all 12 liver tissues, was used for targeted protein quantification to obtain the membrane protein expression of OATP1B1, OATP1B3, and OATP2B1. The surrogate peptide levels in the selected liver sample (black bars) and in membrane fractions of stably transfected HEK293 cells (white bars) are shown in fmol/μg membrane protein (mean ± standard deviation for three measurements (or mean ± range for two measurements, OATP1B1 in vitro, indicated with \*). (b--c). Predicted CL~int,uptake~ of atorvastatin by OATP1B1 (yellow), OATP1B3 (red), and OATP2B1 (blue) without inhibitor or with 10 μM pravastatin, erlotinib or atazanavir (d). Tabulated values of predicted CL~int,uptake~, contribution of each OATP to the overall uptake CL as well as remaining individual or overall OATP dependent CL~int,uptake~ of atorvastatin in the absence of an inhibitor or in the presence of 10 μM of each of the 13 selected inhibitors (e).](jm-2012-00212s_0011){#fig10}

### Maximal Transport Activity Predicts Hepatic Uptake Clearance of Atorvastatin {#sec2.9.2}

Atorvastatin, a substrate of all three OATPs,^[@ref7],[@ref17]^ was used in in vitro to in vivo extrapolations because its liver uptake is mainly dependent on OATP transporters. The intrinsic uptake clearance (CL~int,uptake~) of atorvastatin for each transporter in the in vitro experiments was extrapolated to corresponding in vivo data using the MTA. As can be seen in Figure [10](#fig10){ref-type="fig"}d, OATP1B1 and OATP1B3 were the major OATP transporters responsible for the hepatic uptake of atorvastatin in vivo, with predicted CL~int,uptake~ of 450 and 370 μL/min/g liver, respectively. This corresponds to a contribution to the overall uptake CL of atorvastatin of 52% and 42%, respectively, while the remaining 6% is cleared by OATP2B1.

### Impact of the Maximal Transport Activity on Drug--Drug Interactions {#sec2.9.3}

Using a static mathematical model and assuming competitive inhibition, the impact of 10 μM of the 13 selected inhibitors on hepatic atorvastatin uptake CL in vivo was estimated.^[@ref18]^ The results indicated that pravastatin, identified as a specific inhibitor of OATP1B1 in this study, almost exclusively inhibited the uptake of atorvastatin by OATP1B1 (75% reduction) with only a minor impact on the uptake by OATP1B3 and OATP2B1 (15% and 5% reduction, respectively) (see Figure [10](#fig10){ref-type="fig"}d--e). As a result of the pronounced OATP1B1 inhibition, the uptake CL became more dependent on OATP1B3 and OATP2B1 compared to the situation without an inhibitor. In total, the overall CL~int,uptake~ was reduced by 45% in the presence of pravastatin.

Erlotinib, on the other hand, identified by us as a specific inhibitor of OATP2B1, primarily decreased the contribution of OATP2B1 to atorvastatin uptake (CL~int,uptake~ reduced from 53 to 2.7 μL/min/g liver, a reduction of the remaining transporter activity by 95%). However, due to the low contribution of OATP2B1, the total reduction of the overall CL~int,uptake~ in the presence of erlotinib was only 32% (see Figure [10](#fig10){ref-type="fig"}e). In fact, inhibition of OATP1B1 by erlotinib had a larger impact on overall atorvastatin uptake CL in quantitative terms (CL~int,uptake~ by OATP1B1 reduced from 450 to 290 μL/min/g liver, i.e., a 36% reduction) than the inhibition of OATP2B1. This can be explained by a combination of a higher MTA for OATP1B1 and a lower affinity of atorvastatin for OATP2B1.

Atazanavir, identified as a general inhibitor in this study, inhibited the uptake of atorvastatin by all three OATPs. Overall, uptake CL was decreased by 91% and the remaining uptake CL was mainly dependent on OATP1B1 (Figure [10](#fig10){ref-type="fig"}d). Finally, sulfasalazine, a borderline general inhibitor with a preference for OATP1B1 over OATP1B3, had a large impact on OATP1B1 mediated uptake (95% reduction). This resulted in a clear shift in the contribution of each transporter to the overall uptake of atorvastatin, increasing the OATP1B3 contribution from 42% to 85%. Thus, in this case, OATP1B3 became the major transporter contributing to atorvastatin uptake (Figure [10](#fig10){ref-type="fig"}e).

In general, for all these DDIs, the contribution of OATP2B1 to the uptake CL of atorvastatin was minor. This is a result of the lower MTA of OATP2B1 in combination with the lower affinity for atorvastatin as compared to OATP1B1 and OATP1B3. With some inhibitors though, the OATP2B1 contribution increased up to 6-fold (e.g., cyclosporine A and rifampicin being OATP1B1/OATP1B3 specific inhibitors) (see Figure [10](#fig10){ref-type="fig"}e). However, it should be noted that even in cases where the OATP2B1 contribution increases as compared to the other two OATPs, the maximal OATP2B1 CL~int,uptake~ of atorvastatin cannot exceed 53 μL/min/g liver. This clearly highlights the importance of OATP1B1 and OATP1B3 as atorvastatin uptake transporters. Nevertheless, the importance of OATP2B1 interactions will increase for substrates with higher affinity for OATP2B1 than for the other OATPs.

Discussion {#sec3}
==========

Liver expressed OATPs are considered some of the most important drug transporting proteins in humans and the pharmaceutical industry is recommended to examine new drug candidates for probable interactions with these proteins.^[@ref2]^ This has created a need for in vitro screening of OATP mediated DDIs in drug discovery.^[@ref2],[@ref19]^ A problem when investigating such interactions is that many of the proposed inhibitors of OATP transporters have not been studied for their specificity toward the three hepatic OATPs. We therefore set out to investigate the inhibitor specificity for a data set of 225 structurally diverse oral drugs and drug-like compounds enriched with known and putative OATP inhibitors. We also introduced the maximal transport activity which allows determination of the maximal transport capacity of each transport protein in the human liver in vivo.

While several studies on OATP1B1 mediated drug interactions have been performed previously (cf. ref ([@ref3],[@ref7])), less is known about global drug interaction patterns with OATP1B3 and, in particular, OATP2B1. Here, we observed a large overlap between the inhibitors of the three OATPs and especially between OATP1B1 and OATP1B3, which is in agreement with the high (80%) amino acid sequence homology between these two transporters.

No crystal structures of the OATPs are available, but attempts to develop pharmacophore models from smaller data sets suggest that hydrogen bond features and lipophilicity are important properties of OATP1B1 substrates.^[@ref20]^ This agrees well with an interesting aspect of the OATP inhibitors in this study; they benefit from being both lipophilic and being polar. While NNLogP has been positively correlated to inhibition of both efflux and uptake transporters, PSA has either not been identified as an important molecular property or has been negatively correlated to inhibition of other hepatic transporters in previous studies.^[@ref8],[@ref15],[@ref21]^ As shown here for the investigated compounds, a larger PSA generally results in a lower NNLogP. Hence, a number of different structures may exhibit inhibitory characteristics. A large structural diversity has also been observed for inhibitors of E17βG uptake in human hepatocytes, which, presumably, is mainly the result of inhibition of OATP1B1/OATP1B3.^[@ref22]^

The result that inhibitors benefit from increase in both lipophilicity and polar surface area supports the speculation that there are several interaction sites for these transporters and that a variety of different structures may act as inhibitors of OATP1B1, OATP1B3, and OATP2B1. Although most inhibition curves had slopes close to 1, the existence of several binding sites could explain the few exceptions with slopes much less than unity (see Figure [9](#fig9){ref-type="fig"} and [Supporting Information Table 2](#notes-1)). Results supporting the existence of two binding sites have previously been provided for OATP1B1^[@ref23]^ and for OATP2B1^[@ref24]^ based on biphasic uptake kinetics of E3S. In addition, allosteric interaction sites affecting the uptake of pravastatin by OATP1B1 and OATP1B3 were discussed in a recent publication.^[@ref25]^

The number of inhibitors of each transporter was sufficiently large to investigate molecular descriptors of importance for inhibition of the individual OATP transporters and to develop in silico models that are able to predict inhibition with good accuracy. Our modeling reveals the somewhat different behavior of OATP2B1 relative to OATP1B1 and OATP1B3 (Figure [7](#fig7){ref-type="fig"}c--e). The OATP2B1 model, contrary to those of the other two transporters, has a negative contribution of nonpolar (NPSA) and total surface area (TSA). However, as shown in Table [4](#tbl4){ref-type="table"}, the OATP2B1 inhibitors have a significantly higher NPSA and TSA than the noninhibitors. This may be explained by the presence of a subgroup of OATP2B1 noninhibitors with large NPSA and TSA (e.g., cyclosporine A, ivermectin, and PSC833). The linear model thus includes a negative contribution of these descriptors, enabling correct predictions of OATP2B1 inhibition potency also for such compounds.

Among the compounds classified as specific OATP1B1 inhibitors, we find the three statins, lovastatin acid, pravastatin acid, and simvastatin acid. This is in line with the impact of OATP1B1 polymorphisms on the pharmacokinetics^[@ref26]^ and dynamics^[@ref4]^ of statins. For OATP1B3, only three specific inhibitors could be identified (the novel inhibitor Hoechst 33342, as well as the previously known interacting drugs mitoxantrone and vincristine^[@ref27]^). Erlotinib, a tyrosine kinase inhibitor used in the treatment of several forms of cancer,^[@ref28]^ was the only strong selective OATP2B1 inhibitor identified. Comparison with the maximum unbound plasma concentration of erlotinib (0.4 μM^[@ref29]^) reveals that erlotinib probably inhibits OATP2B1 at clinically relevant concentrations.

Erlotinib also inhibits several other transporters, including the abundantly expressed organic cation transporters OCT1^[@cit1a]^ and multidrug and toxin extrusion 2K (MATE2K)^[@ref29]^ as well as the ABC transporters BCRP, MDR1,^[@ref30]^ and MRP7.^[@ref31]^ This complexity is shared by many other inhibitors in this study. Pravastatin, here identified as an OATP1B1 specific inhibitor, has been reported to be a substrate of MDR1, BCRP, and MRP2.^[@ref32]^ Sulfasalazine, here classified as a borderline general OATP inhibitor, is also a substrate of BCRP.^[@ref33]^ Finally, MK571, identified as a general ABC inhibitor by Matsson and co-workers,^[@ref8]^ was also identified as an OATP inhibitor in this study with IC~50~ values ranging between 2.9 and 6.4 μM as compared to 26 μM (MDR1), 50 μM (BCRP), and 10 μM (MRP2) for the ABC transporters.^[@ref8]^ This analysis emphasizes the significant impact of interactions with various drug transporting proteins on the pharmacokinetics of drugs. We conclude that to be interpretable, screening studies of transporter interactions in drug discovery should be performed under conditions that allow for the investigation of each transport protein in isolation. For this purpose, the new specific and general inhibitors of the three OATPs found in this study will be useful tools.

On the basis of this study, we suggest pravastatin and erlotinib as specific in vitro inhibitors of OATP1B1 and OATP2B1, respectively. In addition, we conclude that cyclosporine A and rifampicin can be used as OATP1B1/OATP1B3 inhibitors, with little effect on OATP2B1. We also confirm the recommendation of ritonavir as a general OATP inhibitor^[@ref2]^ and suggest atazanavir as another general OATP inhibitor. Finally, when considering a general inhibitor of both the hepatic OATPs and ABC transporters, MK571 is the compound with the highest potential, taking into account the results from this as well as from previous studies.^[@ref8]^

Given the complexity of drug interaction patterns with transport proteins, it may seem impossible to predict the in vivo impact of such interactions. Here, we present a new approach to handle this issue for individual transporters. By introducing the concept of MTA, the transport capacity in vitro (*V*~max~) can be linked to the transport activity in the human liver in vivo. The major underlying assumption is that all transport proteins in the isolated membrane fractions are available for drug transport both in vitro and in vivo (see [Experimental Details](#sec4) for additional assumptions with respect to eq [7](#eq7){ref-type="disp-formula"}). When this is the case, the maximal transport capacity is directly linked to the *V*~max~ value in the in vitro model and a scaling factor giving an assumed *V*~max~ value in vivo can be obtained according to eq [7](#eq7){ref-type="disp-formula"}. We underscore that the MTA represents an ideal situation, where it is assumed that all transport protein is active. For instance, intracellular pools of transport proteins are not accounted for. It has been stated, however, that OATPs are not stored in intracellular compartments.^[@ref34]^

As in previously published work, based on the so-called relative expression factor,^[@cit5a]^ the highest relative protein expression was observed for OATP1B1. The large variability in OATP1B1 expression between donors (Figure [10](#fig10){ref-type="fig"}a) could be a result of variable expression due to common genetic variants of this protein.^[@ref19],[@ref35]^ This is in line with previous studies, where similar interindividual variations in human liver OATP expression have been reported.^[@cit1b],[@ref36]^ In addition, the protein expression levels obtained using targeted protein quantification were in reasonably good agreement with these reports.^[@cit1b],[@ref36]^

Because we identified atorvastatin as a substrate of all three OATPs in this study, we could compare the uptake clearance values of the three OATP transporters in vitro. As can be seen in Table [2](#tbl2){ref-type="table"}, OATP2B1 transported atorvastatin with the highest efficiency (*V*~max~/*K*~m~) in vitro. This is presumably due to a high OATP2B1 expression in the in vitro cell model. When taking the MTA into account to calculate intrinsic uptake clearance in the human liver, the contribution of OATP2B1 mediated transport to the overall uptake clearance of atorvastatin was however reduced to a minimum.

The impact of a series of inhibitors with different inhibition patterns (IC~50~ values) on each of the OATPs was markedly altered when the MTA was considered. One such example is erlotinib, where the inhibition of OATP1B1 and OATP1B3 was more significant than the OATP2B1 inhibition in quantitative terms even though erlotinib was identified as an OATP2B1 specific inhibitor (Figure [10](#fig10){ref-type="fig"}d). Importantly, this finding does not preclude the application of erlotinib as a highly specific OATP2B1 inhibitor under controlled in vitro conditions. Note that for the predictions in Figure [10](#fig10){ref-type="fig"}d--e, a fixed concentration of 10 μM was used for all inhibitors. However, if evaluating the risk of clinical DDIs, unbound plasma concentrations in vivo are the most accurate input variables to use (cf. ref ([@ref2])).

Interestingly, the substantial contribution of OATP1B3 to atorvastatin uptake clearance as well as the overlapping specificities of many inhibitors suggest that OATP1B3 is more important for known clinical DDIs than previously understood. For example, both cyclosporine and rifampicin have been reported to affect atorvastatin pharmacokinetics in clinical studies.^[@ref19]^ Cyclosporine is an inhibitor of several drug transporters and metabolizing enzymes.^[@ref2],[@ref37]^ In vivo, concomitant administration of atorvastatin and cyclosporine has resulted in vastly increased plasma concentrations of atorvastatin (7.4--15.3-fold increase (cf. ref ([@ref19]))). This effect has mainly been attributed to inhibition of OATP1B1 mediated uptake and inhibition of CYP dependent metabolism (cf. ref ([@ref38])). Our results, taking MTA into consideration, reveal that inhibition of OATP1B3 mediated uptake of atorvastatin might be almost equally important as OATP1B1 inhibition. Indeed, for both OATP1B1 and OATP1B3, only 11--12% of the predicted activity is remaining when the dual OATP1B1/OATP1B3 inhibitor cyclosporine is used (Figure [10](#fig10){ref-type="fig"}e).

With rifampicin, a similar situation prevails. Concomitant single-dose treatment with atorvastatin and rifampicin has resulted in 6.8-fold increased plasma concentration in vivo, which has been attributed to OATP1B1.^[@ref39]^ Also here, our results indicate that rifampicin greatly reduces both OATP1B1 and OATP1B3 mediated atorvastatin uptake (Figure [10](#fig10){ref-type="fig"}e). Hence, the role of OATP1B3 needs to be reconsidered. In light of the large inhibitor overlap between OATP1B1 and OATP1B3 displayed in Figure [4](#fig4){ref-type="fig"}, it is likely that similar conditions will apply for other drugs administered in combination with a shared OATP1B1/OATP1B3 substrate. Clarithromycin (73.1% inhibition of OATP1B1, 53.8% inhibition of OATP1B3), which has been reported to increase atorvastatin AUC 4.5-fold, could be one such example.^[@ref40]^

Conclusion {#sec99}
==========

In summary, our results speak in favor of considering transporter expression levels in DDI studies. As exemplified above, many of the compounds identified as OATP inhibitors also interact with other drug transporters in vitro. The importance of individual interactions for the overall in vivo drug disposition of a compound is difficult to determine without knowledge of differences in protein expression levels between systems. As more quantitative information on transporter protein levels become available, more accurate scaling from in vitro to in vivo can be performed, which will further improve predictions of drug disposition and DDIs. Importantly, the MTA introduced here does not only apply to the liver. It can also be applied in predictions of transporter impact in other cells and tissues.

Experimental Details {#sec4}
====================

Chemicals {#sec4.1}
---------

The 225 compounds investigated in the inhibition assays were obtained from Sigma-Aldrich Corp. (St. Louis, MO, USA), Toronto Research Chemicals Inc. (North York, ON, Canada), International Laboratory USA (San Bruno, CA, USA), 3B Scientific Corp. (Libertyville, IL, USA), and AstraZeneca (Mölndal, Sweden). Bufuralol was kindly provided by Dr. Inger Johansson, Karolinska Insititutet, Stockholm, Sweden. Aciclovir, amantadine, buspirone, daidzein, doxazosin, etoposide, fenofibrate, fluoxetine, fluvoxamine, furafylline, lamotrigine, mitoxantrone, nifedipine, ofloxacin, phenylbutazone, procainamide, propranolol, ranolazine, sanguinarine, sulfaphenazole, tetraethylammonium, tolbutamide, tranylcypromine, valproic acid, and verapamil were obtained as DMSO stocks from LOPAC (Sigma-Aldrich Corp., St. Louis, MO, USA). Radioactively labeled E17βG (^3^H-E17βG) and E3S (^3^H-E3S) were purchased from PerkinElmer (Waltham, MA, USA).

Compound Selection {#sec4.2}
------------------

A data set of structurally diverse compounds previously used in a study of OATP1B1 inhibition was used as a starting point for the compound selection.^[@ref7]^ This data set contained compounds reflecting the oral drug space as well as compounds identified in the literature as interacting with OATPs. The data set was further expanded with compounds highlighted in the recently published review on drug transporters by the international transporter consortium.^[@ref2]^ Compounds generally used as substrates, inhibitors, or inducers in CYP studies were also included in the final data set.^[@ref13]^

Establishment of Stable Cell Lines and Cell Cultivation {#sec4.3}
-------------------------------------------------------

Total human liver RNA was obtained from Clontech (Mountain View, CA, USA). Reverse transcription was performed using the SuperScript III first-strand synthesis supermix according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). The resulting cDNA was used as a template when *SLCO1B3*/OATP1B3 and *SLCO2B1*/OATP2B1 were amplified using Platinum *Pfx* DNA polymerase (Invitrogen, Carlsbad, CA, USA) and gene specific primers (see [Supporting Information Table 3](#notes-1)). The PCR products were cloned into the *Bam*HI/*Xho*I (OATP1B3) or the *Hind*III/*Eco*RV (OATP2B1) sites of the expression vector pcDNA5/FRT (Invitrogen, Carlsbad, CA, USA). The sequences of the obtained OATP1B3-pcDNA5/FRT and OATP2B1-pcDNA5/FRT constructs were verified by DNA sequencing and were found to be identical with the *SLCO1B3*\**2* (the most common *SLCO1B3* allele having an allele frequency of up to 88% in Caucasians^[@ref41]^) and *SLCO2B1*\**1* (NCBI *SLCO2B1* reference sequence: NM_007256) alleles, respectively. HEK293 Flp-In cells (Invitrogen, Carlsbad, CA, USA) were transfected with the constructed OATP1B3- and OATP2B1-pcDNA5/FRT expression vectors and further selected using hygromycin B (Invitrogen, Carlsbad, CA, USA) as previously described for OATP1B1 and mock transfected cells.^[@ref7]^ HEK293 cells were used because the endogenous background expression of transport proteins and drug metabolizing enzymes is either very low or absent.^[@ref42]^ For continued maintenance, all stable clones were cultured as described by Karlgren et al.^[@ref7]^

Transport Experiments {#sec4.4}
---------------------

Two days prior to transport experiments with E17βG or E3S,^[@ref43]^ OATP1B1,^[@ref7]^ and OATP2B1 overexpressing cells were seeded in 96-well CellBind plates (Corning, Amsterdam, Netherlands) at a density of 100000 cells per well. For all experiments with OATP1B3 expressing cells or with atorvastatin as substrate, cells were seeded in 24-well CellBind plates (Corning, Amsterdam, Netherlands) three days prior to transport experiments at a density of 600000 cells per well. Cell density was optimized by computer assisted experimental design using MODDE 7.0 (Umetrics, Umeå, Sweden) as described elsewhere.^[@ref7]^ For culturing in 96- and 24-well plates, Flp-In-293 medium without phenol red and hygromycin B was used.^[@ref7]^

### Characterization of OATP1B1, OATP1B3, and OATP2B1 Mediated Transport {#sec4.4.1}

To determine the binding affinity (*K*~m~) and maximal transport rate (*V*~max~) of the OATP1B1 and OATP1B3 mediated uptake of model substrate (E17βG), OATP1B1-HEK293 cells grown in 96-well plates were incubated with a solution containing 1 μCi/mL (20.4 nM) of ^3^H-E17βG and 0.5--100 μM of unlabeled E17βG in HBSS, and OATP1B3-HEK293 cells grown in 24-well plates were incubated with a solution containing 2 μCi/mL (40.9 nM) of ^3^H-E17βG and 1--100 μM of unlabeled E17βG in HBSS. The *K*~m~ and *V*~max~ of the OATP2B1 model substrate, E3S, were determined using OATP2B1-HEK293 cells grown in 96-well plates. The cells were incubated with a solution containing 1 μCi/mL (21.9 nM) of ^3^H-E3S and 0.5--600 μM of unlabeled E3S in HBSS. The uptake of model substrate was analyzed using a scintillation counter as described below. To characterize the OATP1B3 and OATP2B1 mediated atorvastatin uptake, cells grown in 24-well plates were incubated with a solution containing 0.01--20 μM atorvastatin in HBSS and intracellular accumulation was analyzed using LC-MS/MS as previously described.^[@ref7]^

Uptake kinetics of E17βG, E3S, and atorvastatin were assessed by plotting the initial uptake rate (uptake after 1 min) against substrate concentration \[S\], and the apparent *K*~m~ and *V*~max~ were determined using nonlinear regression (Prism v.4.02 from GraphPad Software, La Jolla, CA, USA) fitted to eq [2](#eq2){ref-type="disp-formula"}.where *P*diff is the passive permeability of the substrate.

Substrate concentrations well below the *K*~m~ were selected for subsequent inhibition studies with the radiolabeled model compounds. Linearity of E17βG and E3S uptake over time, in the three OATP expressing HEK293 cell lines, was assessed using the selected substrate concentrations for up to 10 min incubation time. The OATP1B1 and OATP1B3 mediated uptake of E17βG was linear over the first 10 min, and the OATP2B1 mediated uptake of E3S was linear for the first 5 min. All uptake experiments were performed in the linear interval.

### Single-Point Inhibition Studies {#sec4.4.2}

The screening for inhibition of OATP1B1 mediated uptake of E17βG was performed at an inhibitor concentration of 20 μM, as previously described.^[@ref7]^ In total, 225 compounds were investigated. Inhibition values for 142 of these compounds were taken from a previous screen of OATP1B1 inhibition.^[@ref7]^

For the OATP1B3 and OATP2B1 single-point inhibition assays, experimental design was used to optimize the assays with regard to substrate concentration, amount of labeled substrate, incubation time, number of washes, cell seeding density, and days in culture before the experiments. The MODDE 7.0 (Umetrics, Umeå, Sweden) software was used for setup and evaluation of the experimental design as described previously.^[@ref7]^ In the OATP1B3 inhibition assay, cells grown in 24-well plates were incubated for 5 min with a solution containing 20 μM of the test compound, 2 μCi/mL (40.9 nM) of ^3^H-E17βG, and 1 μM of unlabeled E17βG in HBSS. In the OATP2B1 inhibition assay, cells grown in 96-well plates were incubated for 4 min with a solution containing 20 μM of the test compound, 1 μCi/mL (21.9 nM) of ^3^H-E3S, and 1 μM of unlabeled E3S in HBSS. All 225 compounds in the data set were screened for OATP1B3 and OATP2B1 inhibition.

On each plate, HEK293 cells were incubated with substrate solution as a positive control of OATP mediated uptake (OATP expressing cells) and the passive permeability was obtained from mock transfected cells. In addition, pitavastatin, taurocholate, or atorvastatin was included on each plate as a positive control of inhibition. Percent inhibition was calculated according to eq [3](#eq3){ref-type="disp-formula"}.

A compound was classified as an inhibitor if it decreased the uptake of model substrate by at least 50% (2-fold decrease).^[@ref7],[@ref8],[@ref15],[@ref21]^ Likewise, a compound was classified as a stimulator if it increased the uptake by at least 100% (2-fold increase).

### IC~50~ Determinations {#sec4.4.3}

The half-maximal inhibitory concentration, IC~50~, for a subset of 13 compounds was determined in vitro, using the same methodology as in the single-point inhibition studies. To include potential "OATP specific" inhibitors in a broader sense, OATP inhibitors not identified as inhibitors of the ABC-transporters MDR1, BCRP, MRP2, and/or the organic cation transporter OCT1 in previously published studies^[@ref8],[@ref15]^ were selected from the data set. With this prerequisite, five of the 13 compounds, identified as either specific (doxorubicin, erlotinib, indometacin, and vincristine) or general (sulfasalazine) OATP inhibitors in the single-point inhibition assays, were selected. Additionally, three compounds recommended as OATP inhibitors (rifampicin, ritonavir, and cyclosporine A),^[@ref2]^ three commonly used ABC inhibitors (Hoechst 33342, KO143, and MK571),^[@ref8]^ and two compounds belonging to drug classes with clinically relevant OATP mediated drug--drug interactions (atazanavir and pravastatin) were investigated. In the IC~50~ experiments, 5--12 inhibitor concentrations were used in the following concentration intervals: atazanavir 0.02--40 μM, cyclosporine A 0.01--25 μM, doxorubicin 0.1--1000 μM, erlotinib 0.02--400 μM, Hoechst 33342 0.1--600 μM, indometacin 0.1--600 μM, KO143 0.05--10 μM, MK571 0.01--100 μM, pravastatin 0.1--400 μM, rifampicin 0.05--400 μM, ritonavir 0.01--50 μM, sulfasalazine 0.01--100 μM, and vincristine 0.1--600 μM. IC~50~ values were calculated by fitting the data to the following equation using Prism v.4.02 (GraphPad Software, La Jolla, CA, USA).

This is equal to the four-parameter equation when the bottom plateau of the curve is constrained to zero and the top plateau to 100. \[I\] is the inhibitor concentration, and the Hill Slope describes the steepness of the curve.

The inhibition constant, *K*~i~, was calculated according to eq [5](#eq5){ref-type="disp-formula"} (assuming competitive inhibition).

In parallel to the experimental determinations, predicted IC~50~ values for the 13 compounds were calculated based on the obtained single-point inhibition results using eq [6](#eq6){ref-type="disp-formula"}.

Compounds showing negative inhibition values (i.e., stimulation of the uptake) in the single-point inhibition studies, and compounds where no experimental IC~50~ value could be determined, were excluded from the IC~50~ predictions.

### Scintillation Analysis {#sec4.4.4}

At the end of the incubation with radioactively labeled substrate solutions, carrier-mediated uptake was stopped by addition of ice-cold PBS followed by three or four washes. The cells were lysed using 1 M NaOH. Analysis of intracellular accumulation of radioactively labeled model substrate was carried out on a TopCount NXT scintillation counter using Luma plates (OATP1B1 and OATP1B3) or Opti plates with addition of 250 μL of Microscint 20 scintillation liquid (OATP2B1), respectively. All plates, scintillation liquids, and equipment were obtained from PerkinElmer, Inc. (Downers Grove, IL, USA).

### Protein Concentration Measurements {#sec4.4.5}

In all uptake kinetics or inhibition experiments, cell lysates (obtained by addition of 1 M NaOH as described above) were neutralized using 1 M HCl. Total protein content was measured using the BCA Protein Assay Reagent Kit (Pierce Biotechnology, Rockford, IL, USA) according to manufacturer's instructions.

### Statistics {#sec4.4.6}

All experiments were performed in duplicate (OATP1B3) or triplicate (OATP1B1 and OATP2B1) on 2--6 independent occations. In each experiment, ANOVA and Dunnett's multiple comparison test were used to ensure that the uptake in presence of inhibitor/stimulator was significantly different from the positive OATP control where no inhibitor/stimulator was used.

Molecular Descriptors {#sec4.5}
---------------------

The 225 compounds used in this study, together with an oral drug reference data set,^[@ref8]^ were treated in their neutral states and characterized using the AZ oeSelma descriptors generated from SMILES (see [Supporting Information Table 4](#notes-1) for a compilation of the structures in SMILES format). The AZ oeSelma descriptors consist of AstraZeneca's in-house compilation of 93 molecular descriptors, of physicochemical nature, in line with the work of Labute.^[@ref44]^ These descriptors contain 1D and 2D descriptors, including properties such as various counts of atoms and bonds, charges, surfaces, and lipophilicity. In addition, charge and solubility in water at pH 7.4 were predicted using ADMET Predictor (SimulationsPlus, Lancaster, CA, USA). Significant differences between the groups of inhibitors and noninhibitors, with regard to physicochemical properties, were assessed using the nonparametric Mann--Whitney U test.

Computational Modeling {#sec4.6}
----------------------

The overall characteristics of the data set were assessed using PCA implemented in Simca-P (version 12.0 of the Simca-P software, Umetrics AB, Umeå, Sweden). The data set was also assessed on a PCA model where the 529 oral drugs in the reference data set were used as a training set and the OATP data set was projected onto that model. Modeling of the inhibition of the three transporters (OATP1B1, OATP1B3, and OATP2B1) was performed using the PLS method implemented in Simca-P (version 12.0 of the Simca-P software, Umetrics AB, Umeå, Sweden). Each model was developed as a classification model where the cutoff for inhibition was set to 50%. Compounds exhibiting inhibition greater than 50% were designated as inhibitors (class = 1), and compounds exhibiting inhibition less than 50% were considered to be noninhibitors (class = 0).

For all three models, compounds exhibiting inhibition \<0%, i.e., stimulation of the transport, were excluded from the modeling. The data sets were split into a training set and a test set, where a third of the data set was randomly selected as the test set. Because of skewed distributions of inhibitors and noninhibitors of the three transporters (the former class being between 33% and 38% in the respective training sets), the cutoff value, normally set to 0.5 for equally distributed classes, was adjusted during model development using the training sets to optimize accuracy. The data were mean-centered and scaled to unit variance. A variable selection procedure was applied on the training sets, where variables exhibiting low variable importance were removed stepwise. The aim of the variable selection was to maintain predictability and increase the robustness of the models. At the same time, the complexity of the models was decreased, facilitating interpretation by removing information that was not directly related to the response variable (i.e., noise). The variable selection was validated by the 7-fold cross-validated *R*^2^ (Q^2^) for the training sets. The selected variables for the three transporters were subsequently used to derive the final models and the qualities of these models were judged by the accuracies of the respective test sets.

A general OATP inhibition model was also developed as described above, whereby a compound was defined as an inhibitor if it decreased the uptake of model substrate by any of the three transporters by 50% or more.

Prediction of in Vivo Uptake Clearance {#sec4.7}
--------------------------------------

### Preparation of Cell and Tissue Samples for Protein Expression Analysis {#sec4.7.1}

HEK293 cells stably transfected with OATP1B1, OATP1B3, or OATP2B1 were cultured as described elsewhere^[@ref7]^ until reaching a passage of 19, 17, and 18, respectively. At 95--100% confluence, cells were trypsinized and centrifuged at 450*g* for 5 min, followed by one washing step using phosphate buffered saline (PBS). The resulting cell pellets were frozen at −80 °C until analysis.

Snap-frozen human liver tissue samples were obtained from 12 individual donors undergoing surgical liver resection at Uppsala University Hospital (Uppsala, Sweden), as approved by Uppsala Regional Ethical Review Board (ethical approval no. 2009/028). All donors gave their informed consent. The tissue samples were stored at −80 °C until further analysis.

### Extraction of Membrane Proteins and Measurement of OATP1B1, OATP1B3, and OATP2B1 Protein Expression {#sec4.7.2}

For relative protein quantification, HEK293 cells and liver tissue samples were prepared and analyzed as described previously.^[@ref16],[@ref45]^ Briefly, crude membrane fractions were isolated from the samples and lysed in SDS-containing buffer. Proteins were digested with trypsin according to the FASP protocol, using 30k ultrafiltration units. The digests were loaded on SAX-pipet tip columns at pH 11, and the peptides were eluted with a buffer of pH 2. LC-MS/MS analysis of the samples was carried out on an Orbitrap instrument using 4 h LC gradients. The relative abundances of the proteins were calculated using the total signal intensities of the peptides identifying each protein as determined in the MaxQuant software (Max Planck Institute of Biochemistry, Martinsried, Germany).

For the targeted protein quantification, membrane fractions from the frozen HEK293 cells and from one representative human liver tissue sample were extracted and digested with trypsin as previously described.^[@ref36]^ The targeted OATP proteins were quantified by peptide-based LC-MS/MS measurements as a surrogate of proteins levels, with the addition of stable isotope labeled internal standard peptides that are specific for each OATP.

### In Vitro to in Vivo Extrapolations Using the Maximal Transport Activity {#sec4.7.3}

A static mathematical model was used to estimate the contribution of each OATP to the intrinsic uptake CL (CL~int,uptake~) of atorvastatin in vivo. The model was based on in vitro kinetic results of atorvastatin uptake in OATP overexpressing HEK293 cells. An intersystem extrapolation factor based on the ratio of the OATP protein abundances (obtained using targeted proteomics quantification) in the cell lines (protein expression~in vitro~) to those in human liver tissue (protein expression~in vivo~) was used to calculate the MTA, assuming that the protein expression is directly proportional to the maximal velocity (*V*~max~) and that the amount of membrane protein per total amount of protein is equal in the two systems (see eq [7](#eq7){ref-type="disp-formula"}).

This is in line with previously published work, where the so-called relative expression factor, representing the ratio of protein expression between human hepatocytes and in vitro cell models, measured by Western blotting, was used as an in vitro to in vivo scaling factor.^[@cit5a]^

The intrinsic uptake CL of each OATP was predicted using eq [8](#eq8){ref-type="disp-formula"}:where MTA is the estimated maximal velocity in vivo using the scaling factor explained above, \[S\] is the atorvastatin concentration (*C*~max,unbound~ = 2 nM^[@ref46]^), and HomPPGL is milligrams of homogenate protein per gram of liver (88 ± 14 mg/g, data based on 12 protein measurements using the Pierce 660 nm Protein Assay kit with addition of ionic detergent compatibility reagent (Pierce Biotechnology, Rockford, IL, USA)). The overall intrinsic uptake CL of atorvastatin in vivo was derived as the sum of the intrinsic uptake CL of each individual OATP. This approach is similar to the one described by Proctor et al. for CYPs but with proteomics data used as an intersystem extrapolation factor.^[@ref47]^

Our model was subsequently used to predict the impact of the subset of 13 compounds (for which IC~50~ values were determined) on atorvastatin intrinsic uptake CL at an inhibitor concentration of 10 μM (a concentration where maximal resolution was expected for this subset of compounds, because 49% of the IC~50~ values \<10 μM and 51% of the IC~50~ values \>10 μM), assuming competitive inhibition and using the following equation:^[@ref48]^where *K*~m~ is the atorvastatin concentration at half-maximal velocity in vitro, \[I\] is the inhibitor concentration (10 μM), and *K*~i~ is the inhibition constant determined using eq [5](#eq5){ref-type="disp-formula"}. As above, the overall intrinsic uptake CL of atorvastatin in vivo in presence of an inhibitor was derived as the sum of the intrinsic uptake CL of each individual OATP.

Tables containing an extended version of Table [1](#tbl1){ref-type="table"} (i.e., OATP inhibition data and selected molecular descriptors), Hill slopes for the IC~50~ curves shown in Figure [9](#fig9){ref-type="fig"}, gene specific cloning primers, and SMILES for the investigated compounds, as well as figures showing atorvastatin kinetic uptake curves, overlap between OATP inhibitors and CYP interacting drugs and a comparison of predicted and experimentally obtained IC~50~ values (PDF and XLS). This material is available free of charge via the Internet at <http://pubs.acs.org>..
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CCK-8
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DDI
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E17βG
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E3S
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FDA

:   Food and Drug Administration

HBSS

:   Hank's Balanced Salt Solution

HEK293

:   human embryonic kidney 293 cells
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LC-MS/MS

:   liquid chromatography-tandem mass spectrometry
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MDR
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:   maximal transport activity
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:   nonpolar surface area
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:   organic anion transporting polypeptide
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:   organic cation transporter

PCA

:   principal component analysis

Pgp

:   P-glycoprotein

PLS

:   partial least-squares projection to latent structures
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:   polar surface area

SLC

:   solute carrier

SMILES

:   simplified molecular input line entry system
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